TICKERNERD
Menu
TXGTXGHealthcare · Health Information Services

TXG Stock Forecast: 10X Genomics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$64
−2.06% on the day

The 16 Wall Street analysts covering 10X Genomics, Inc. hold a median 12-month price target of $50 — -21.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$8.5B
Ticker Nerd rank
94 / 100
Median analyst target
$50
Analysts covering
16
Total return, dividends reinvested
1W
+10.0%
1M
+37.8%
YTD
+291.0%
1Y
+346.0%
From 52W high
−2.1%
From 52W low
+462.4%
$11
$65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TXG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 10X Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Accruals
95
Quality
94
Revisions
82
Value
72
Issuance
62
Growth
49
Volatility
43
Size
18

Momentum (99): The shares have been drifting up relative to others.

Volatility (43): The share price moves around a lot.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TXG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TXG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26TXGHigh $65Median $50Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
6 Buy10 Hold0 Sell
Low $40Median $50High $65

The green dot is the last close — the median target sits −21.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
12 Aug 2026Stephens & Co.MaintainsOverweight$50 → $65
10 Aug 2026Canaccord GenuityMaintainsBuy$50 → $60
10 Aug 2026Piper SandlerMaintainsNeutral$42 → $47
7 Aug 2026CitigroupMaintainsNeutral$45 → $50
7 Aug 2026Morgan StanleyMaintainsEqual-Weight$37 → $40
17 July 2026Leerink PartnersMaintainsMarket Perform—
17 July 2026Leerink PartnersMaintainsMarket Perform$23 → $40
14 July 2026Canaccord GenuityMaintainsBuy—
14 July 2026Canaccord GenuityMaintainsBuy$32 → $50
9 July 2026Morgan StanleyMaintainsEqual-Weight$22 → $37
9 July 2026Morgan StanleyMaintainsEqual-Weight—
8 July 2026CitigroupMaintainsNeutral—
8 July 2026CitigroupMaintainsNeutral$24 → $45
1 July 2026Piper SandlerMaintainsNeutral—
24 June 2026BarclaysMaintainsOverweight—
12 May 2026JP MorganMaintainsNeutral—
12 May 2026Morgan StanleyMaintainsEqual-Weight—
20 Apr 2026B of A SecuritiesMaintainsNeutral—
20 Apr 2026Canaccord GenuityMaintainsBuy—
14 Apr 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TXG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

10X Genomics, Inc. (TXG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−186.0×

Cheaper than 99% of US stocks

Price / sales
13.8×

Cheaper than 12% of US stocks

Price / book
10.3×

Cheaper than 10% of US stocks

EV / EBITDA
−194.4×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
−12.7%

Higher than 14% of US stocks

Earnings growth (YoY)
−12.6%

Higher than 24% of US stocks

Gross margin
74.5%

Higher than 87% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−12.2%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−5.0%

Higher than 32% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TXG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
TXG10X Genomics, Inc.$8.5B
94
HQYHealthEquity, Inc.$9.0B
95
HNGEHinge Health, Inc.$6.8B
82
BTSGBrightSpring Health Services, Inc.$11.4B
91
TEMTempus AI, Inc.$13.0B
25
WAYWaystar Holding Corp.$4.8B
34
DOCSDoximity, Inc.$4.7B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 10X Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TXG news & analysis

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

Seeking Alpha · 20 Aug 2026positive

Seeking Alpha upgraded 10x Genomics, stating the turnaround is real but that its Atera platform now needs to deliver. The article notes Atera could boost instrument sales in late 2026 and drive high-margin consumables revenue from 2027, while citing risks such as manufacturing constraints, potential cannibalization of Xenium, competition, and share dilution.

Why it matters — A TXG watcher would care because the upgrade signals growing confidence in the company's turnaround and the commercial potential of its Atera platform, while also flagging the key risks that could affect future performance.

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

Zacks Investment Research · 7 Aug 2026positive

10x Genomics reported second-quarter earnings and revenue that beat analyst estimates, expanded its gross margin, and raised its 2026 revenue outlook, despite experiencing a year-over-year decline in sales.

Why it matters — A TXG watcher would care because the company exceeded expectations on earnings and revenue, improved profitability through margin expansion, and signaled confidence in future growth by lifting its long-term revenue forecast.

10x Genomics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

10x Genomics reported second-quarter revenue of $151 million, which included $1.6 million in license and royalty revenue from its settlement with Takara. Excluding non-recurring settlement revenue, revenue was $149.4 million, up 3% year over year.

Why it matters — The update provides a snapshot of the company's core revenue growth and the financial impact of its legal settlement with Takara.

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of 10x Genomics, Inc.'s Q2 2026 earnings call, covering the company's quarterly financial discussion and management commentary.

Why it matters — The transcript gives TXG watchers direct access to management's statements and the details of the quarter's financial results.

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 6 Aug 2026neutral

Zacks Research reports that 10x Genomics (TXG) posted revenue and EPS for the quarter ended June 2026, and the piece examines how key metrics compare with Wall Street estimates and the previous year's figures. The coverage focuses on how the company's quarterly performance stacks up against expectations and year-ago results.

Why it matters — TXG watchers would care because the comparison of actual quarterly metrics against analyst estimates and prior-year numbers offers a baseline read on the company's operational performance for the period.

FAQ

Frequently asked questions about TXG stock

What is the TXG stock price forecast for 2026-2027?

The 16 Wall Street analysts covering 10X Genomics, Inc. have a median 12-month price target of $50, with estimates ranging from $40 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TXG stock a buy right now?

Of the 16 analysts covering 10X Genomics, Inc., 6 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 10X Genomics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TXG?

As at 22 Aug 2026, 10X Genomics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will TXG stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies -21.6% from the last close, and Ticker Nerd's factor model ranks 10X Genomics, Inc. 94 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TXG stock forecast for 2030?

No analyst covering 10X Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $65 over the next 12 months.

How has TXG stock performed over the past year?

10X Genomics, Inc. returned +346.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 10X Genomics, Inc. do?

10x Genomics Inc. is a life science technology company that provides advanced tools for high-resolution analysis of biological systems.

What is the latest news on TXG?

The most recent item we track (Seeking Alpha, 20 Aug 2026): "10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)". Seeking Alpha upgraded 10x Genomics, stating the turnaround is real but that its Atera platform now needs to deliver. The article notes Atera could boost instrument sales in late 2026 and drive high-margin consumables revenue from 2027, while citing risks such as manufacturing constraints, potential cannibalization of Xenium, competition, and share dilution.

Company

About 10X Genomics, Inc.

10x Genomics Inc. is a life science technology company that provides advanced tools for high-resolution analysis of biological systems. The company focuses on single-cell and spatial biology, offering integrated solutions that combine instruments, consumables, and software for researchers worldwide. Its core product portfolio includes the Chromium platform for single-cell and multiomic analysis, enabling detailed transcriptomic profiling, immune profiling, and other genomic applications at the level of individual cells. 10x Genomics also offers the Visium spatial platform for spatial gene expression studies and the Xenium in situ platform for high-plex tissue profiling, supporting work in oncology, immunology, neuroscience, and other complex disease areas. These technologies are used by academic institutions, pharmaceutical and biotechnology companies, and government research organizations to interrogate biological complexity and generate high-dimensional molecular data. Founded in 2012 and headquartered in Pleasanton, California, United States, 10x Genomics operates across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific, playing a significant role in modern genomics and biomedical research infrastructure.

CEO Dr. Serge Saxonov Ph.D. · 1,178 employees · United States · https://www.10xgenomics.com